Similar Items: Optimization of 1st-line antituberculosis dosing regimens using a population pharmacokinetic approach: food effects, drug combinations and pharmacological effects
- Preclinical pharmacokinetic evaluation of novel antimalarial and antituberculosis drug leads
- The pharmacokinetics and toxicity of antituberculosis agents and other co-administered drugs in children with tuberculosis, with and without HIV infection, and their relationship to nutritional status
- Repurposing chlorpromazine and its metabolites for antituberculosis drug discovery
- Pharmacokinetics and safety of first -- and second--line anti-- tuberculosis drugs in children
- Public Health Impact and Cost-Effectiveness of 2-Dose vs 1-Dose Human Papillomavirus Vaccination Regimen in Saudi Arabia
- A zebrafish larval model for drug-induced hepatic Injury due to first-line antituberculosis drugs and possible prevention/treatment with N-acetyl-cysteine
Author: McIlleron, Helen
- Population pharmacokinetics and pharmacokinetic-pharmacodyamic modeling of antitubercular drugs
- Optimization of 1st-line antituberculosis dosing regimens using a population pharmacokinetic approach: food effects, drug combinations and pharmacological effects
- Pharmacokinetic-Pharmacogenetic-and-Pharmacodynamic Adherence Relationships in Cohort South African HIV Infected Children on Lopinavir-and Nevirapine-Based Regimens
- Population pharmacokinetic models describing drug-drug interactions and variability in HIV infected South Africans on protease inhibitor-based antiretroviral regimens with and without tuberculosis
- Determinants and consequences of the pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in a cohort of tuberculosis patients
- Variability in the pharmacokinetics of rifapentine in South African tuberculosis patients : a classical and population approach